General Announcement::Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
12-May-2020 13:30:20
Status
New
Announcement Sub Title
Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India
Announcement Reference
SG200512OTHRGEMY
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
12/05/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India

Attachments

PR_SGX_12052020.pdf
Total size =1326K